---
title: "Bristol Myers Confirms That They Have Ended Partnership With Cellares, Spokesperson Says"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296941270.md"
datetime: "2026-08-25T16:48:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296941270.md)
  - [en](https://longbridge.com/en/news/296941270.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296941270.md)
generator: "portal-rs"
---

# Bristol Myers Confirms That They Have Ended Partnership With Cellares, Spokesperson Says

Aug 25 (Reuters) - Bristol-Myers Squibb Company (BMY.N) : \* CONFIRM THAT WE HAVE ENDED OUR PARTNERSHIP WITH CELLARES. - BRISTOL MYERS SPOKESPERSON \* BRISTOL MYERS SPOKESPERSON: DETERMINED CELLARES-PARTNERED CELL SHUTTLE SYSTEM COULD NOT MEET NECESSARY REQUIREMENTS TO MAKE COMMERCIAL BREYANZI

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares](https://longbridge.com/en/news/296941366.md)
- [Archer Investment Corp Takes $1.40 Million Position in Bristol Myers Squibb Company $BMY](https://longbridge.com/en/news/297393102.md)
- [BUZZ-Cytokinetics rises after heart disease drug shows promise in late-stage study](https://longbridge.com/en/news/297310247.md)
- [BREAKINGVIEWS-AstraZeneca's blocked M&A signals tough CEO finale](https://longbridge.com/en/news/296766497.md)
- [FDA grants accelerated approval to Bristol Myers Squibb’s ZENBEXUS for relapsed multiple myeloma combo use](https://longbridge.com/en/news/295848217.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**